Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
IPO Year:
Exchange: NYSE
Website: danaher.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $285.00 | Peer Perform → Outperform | Wolfe Research |
| 10/1/2024 | $315.00 | Overweight | Stephens |
| 8/28/2024 | $280.00 | Equal Weight | Wells Fargo |
| 6/3/2024 | $295.00 | Buy | Jefferies |
| 4/17/2024 | $280.00 | Hold → Buy | HSBC Securities |
| 1/24/2024 | $240.00 | Overweight → Equal Weight | Barclays |
| 12/18/2023 | Hold | HSBC Securities | |
| 12/13/2023 | Peer Perform | Wolfe Research | |
| 12/7/2023 | $215.00 → $205.00 | Buy → Neutral | Goldman |
| 7/19/2023 | $270.00 | Outperform | Raymond James |
Baird analyst Catherine Schulte maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $271 to $278.
RBC Capital analyst Conor McNamara maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $297 to $300.
Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Equal-Weight and raises the price target from $270 to $285.
Leerink Partners maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $275 to $280.
In the last three months, 5 analysts have published ratings on Danaher (NYSE:DHR), offering a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 3 0 0 Last 30D 1 0 3 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Danaher, revealing an average target of $269.0, a high estimate of $310.00, and a low estimate of $250.00. This current average reflects an increase of 4.59% fro
Stifel analyst Daniel Arias maintains Danaher (NYSE:DHR) with a Hold and raises the price target from $235 to $250.
Goldman Sachs analyst Matthew Sykes maintains Danaher (NYSE:DHR) with a Neutral and raises the price target from $225 to $250.
TD Cowen analyst Dan Brennan maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $290 to $310.
B of A Securities analyst Derik De Bruin maintains Danaher (NYSE:DHR) with a Neutral and raises the price target from $270 to $275.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
WASHINGTON, Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Third Quarter 2024 Results Net earnings were $818 million, or $1.12 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.71.Revenues increased 3.0% year-over-year to $5.8 billion and non-GAAP core revenue increased 0.5%.Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.2 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Our team delivered strong third quarter resu
WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. Y
BREA, Calif. and TEL AVIV, Israel, Sept. 17, 2024 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. Scopio's X100 / X100HT with FF-BMA Application are CE-Marked. Bone marrow aspirate analysis is a vital procedure providing essential information for the assessment of various hematologic diseases.i By as
WASHINGTON, Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagn
WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event. The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines. For both the third quarter and full year 2024, the Company continues to expect that non-GAAP core revenue will be down low-single digits year-over-year. As previously announced, Danaher will hold an analyst meeting in Washington, D.C. on September 5, 2024
WASHINGTON, Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery, Executive Vice President, Diagnostics. A link to the webcast and accompanying slide presentation will be available on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the video webcast will be available following the presentation. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating
BREA, Calif., July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the DxI 9000 Immunoassay Analyzer* was honored during Premier, Inc.'s annual supplier Innovation Celebration at its 2024 Breakthroughs Conference and Exhibition. The Innovation Celebration recognizes groundbreaking healthcare technologies that have been launched throughout the year and the ways these products are helping to improve the health of communities. With the highest throughput compared to any immunoassay analyzer on the market, Beckman Coulter's
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (C
WASHINGTON, July 16, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year. "At the heart of everything we do at Danaher is our commitment to continuous improvement, and our sustainability program exemplifies this commitment," said Rainer Blair, President and Chief Executive Officer. "We remain focused on making meaningful progress every day and are proud of what we achieved this year across our sustainability initiative
Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies.New technology will work to capture and analyze the highly heterogeneous tumor microenvironment.WASHINGTON, July 11, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, today launched a research collaboration with Stanford University's Department of Bioengineering intended to shape the future of cancer drug screening through "smart microscopy." Combining spatial biology with artificial intelligence (AI), the research team at the Da
WASHINGTON, Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Third Quarter 2024 Results Net earnings were $818 million, or $1.12 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.71.Revenues increased 3.0% year-over-year to $5.8 billion and non-GAAP core revenue increased 0.5%.Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.2 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Our team delivered strong third quarter resu
WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. Y
WASHINGTON, Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagn
WASHINGTON, June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You
WASHINGTON, May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 26, 2024 to holders of record on June 28, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses a
WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key First Quarter 2024 Results Net earnings were $1.1 billion, or $1.45 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.92.Revenues decreased 2.5% year-over-year to $5.8 billion and non-GAAP core revenue decreased 4.0%.Operating cash flow was $1.7 billion and non-GAAP free cash flow was $1.4 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "We had a good start to 2024, with our team deliv
WASHINGTON, March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You
WASHINGTON, Feb. 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 26, 2024 to holders of record on March 28, 2024. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses an
WASHINGTON, Jan. 30, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2023 Results Net earnings were $1.1 billion, or $1.50 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.09.Revenues decreased 10.0% year-over-year to $6.4 billion.Non-GAAP core revenue decreased 11.5%, including a 4.5% non-GAAP base business core revenue decline.Operating cash flow was $1.6 billion and non-GAAP free cash flow was $1.2 billion.Key Full Year 2023 Results Net earnings were $4.
WASHINGTON, Jan. 8, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2023 performance in a presentation at the J.P. Morgan Healthcare Conference at 2:15 p.m. ET. For the fourth quarter 2023, estimated revenues are anticipated to decrease in the low-double digit percent range year-over-year.Estimated non-GAAP core revenue for the fourth quarter of 2023 is expected to decline in the low-double digit percent range, which would be above the Company's previously announced guidance of a high-teens percent decline.Estimated non-GAAP base business core
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
10-Q - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
144 - DANAHER CORP /DE/ (0000313616) (Subject)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
11-K - DANAHER CORP /DE/ (0000313616) (Filer)
SD - DANAHER CORP /DE/ (0000313616) (Filer)
IRANNOTICE - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
10-Q - DANAHER CORP /DE/ (0000313616) (Filer)
Wolfe Research upgraded Danaher from Peer Perform to Outperform and set a new price target of $285.00
Stephens initiated coverage of Danaher with a rating of Overweight and set a new price target of $315.00
Wells Fargo initiated coverage of Danaher with a rating of Equal Weight and set a new price target of $280.00
Jefferies resumed coverage of Danaher with a rating of Buy and set a new price target of $295.00
HSBC Securities upgraded Danaher from Hold to Buy and set a new price target of $280.00
Barclays downgraded Danaher from Overweight to Equal Weight and set a new price target of $240.00
HSBC Securities initiated coverage of Danaher with a rating of Hold
Wolfe Research resumed coverage of Danaher with a rating of Peer Perform
Goldman downgraded Danaher from Buy to Neutral and set a new price target of $205.00 from $215.00 previously
Raymond James initiated coverage of Danaher with a rating of Outperform and set a new price target of $270.00
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (C
WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service. Ms. Sawyer Montgomery, currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair. Rainer Blair com
Move reflects increasing investment in AI as driving force for innovation and productivity.Company will host Innovation Summit in December focused on AI in R&D.WASHINGTON, June 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, today announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role. Jose-Carlos Gutierrez-Ramos, Senior Vice President and Chief Science Officer, Danaher, said: "We are delighted to welcome Dr. Stumpe to our team. His extensive experience in leveraging AI to drive scientific and operational progress will be critical in further supporting
New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract fundingNobel laureate Doudna and team to partner with Danaher to oversee center's translational and clinical researchWASHINGTON, Jan. 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) and the Innovative Genomics Institute (IGI) today launched a collaborative center to develop gene-editing therapies fo
NEW YORK, Sept. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, the S&P MidCap 400 and the S&P SmallCap 600 indices: Veralto Corp. (NYSE:VLTO) will be added to the S&P 500 effective prior to the open of trading on Monday, October 2, replacing DXC Technology Co. (NYSE:DXC) which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Tuesday, October 3. DXC Technologies will replace Ebix Inc. (NASD: EBIX) in the S&P SmallCap 600 also effective prior to the open of trading on October 3. S&P 500 &100 constituent Danaher Corp. (NYSE:DHR) is spinning off Veralto in a transaction expected to be completed on October 2. Followin
Investments set foundation for global platform of laboratory-automation technologies serving environmental, agricultural and food-and-beverage applications Battery Ventures, a global, technology-focused investment firm, today announced the creation of a new laboratory-automation platform following recent acquisitions of three complementary companies: Skalar Analytical, PromoChrom Technologies and LCTech. Skalar Analytical, based in Breda, the Netherlands, manufactures a range of chemistry analyzers and laboratory-automation solutions for environmental and agricultural applications. Skalar serves as the foundation for the new platform, while PromoChrom—which is based in Richmond, British
WASHINGTON, June 29, 2022 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members. Mr. Dewan is currently CEO of Arena Holdings Management, a global investment business. From 2003 to 2015, he worked at Tiger Global Management, most recently as Head of Public Equities. Prior to that, Mr. Dewan was a private equity investor at Silver Lake Partners. Mr. Dewan earned his B.S. in Engineering with a Certificate in Applied and Computational Mathematics from Princeton University. Steven M. Rales, Chai
CORALVILLE, Iowa, Sept. 1, 2021 /PRNewswire/ -- Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced today that Demaris Mills has been appointed President of the Company, succeeding Trey Martin, who was promoted to a new position in Genomic Medicine within Danaher, IDT's parent company. The leadership transition comes at a time when IDT is growing its product solutions, expanding its global footprint, has a seasoned leadership team, and has the advantage of the Danaher Business System (DBS) culture. Mills has been with Danaher comp
WASHINGTON, Aug. 24, 2021 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced that, effective April 1, 2022, Georgeann F. Couchara will succeed Angela S. Lalor as Senior Vice President, Human Resources. At that time, Ms. Lalor will move to a part time, advisory role until her retirement in the first quarter of 2023. Ms. Couchara, currently Vice President, Talent for the Company, will join the Danaher Leadership Team and the Office of the Chief Executive, reporting to Rainer M. Blair, Danaher's President & Chief Executive Officer. Additionally, the Company announced that Christopher M. Bouda will succeed Robert S. Lutz as Chief Accounting Officer of Danaher, effect
WASHINGTON, May 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed A. Shane Sanders to its Board of Directors and to its Audit Committee. This addition expands the size of Danaher's Board from twelve to thirteen members. Mr. Sanders is currently Senior Vice President of Business Transformation at Verizon Communications Inc. (NYSE:VZ). Since joining Verizon in 1997, he has served in a series of progressively more responsible leadership positions including as Senior Vice President of Corporate Finance from 2015 to 2020. Prior to joining Verizon, Mr. Sanders served in various finance roles at Hallmark Cards, Inc. and Safelite Glass Corporation, and beg